06:31 , Aug 10, 2018 |  BC Week In Review  |  Company News

Luoxin gains Chinese rights to Trulance

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug Trulance plecanatide in China, including Hong Kong and Macau. The license covers the...
19:36 , Aug 7, 2018 |  BC Extra  |  Company News

Luoxin gains Chinese rights to Trulance

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug Trulance plecanatide in China, including Hong Kong and Macau. The license covers the...
17:21 , Jul 20, 2018 |  BC Week In Review  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on July 17. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE, Sinovant...
16:13 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Ironwood, Allergan start Phase IIIb of Linzess in IBS-C

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) began a double-blind, placebo-controlled, U.S. Phase IIIb trial to evaluate 290 µg Linzess linaclotide once daily in about 600 patients with irritable bowel syndrome with constipation (IBS-C). The...
21:55 , Jul 17, 2018 |  BC Extra  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on a newsy Tuesday. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE,...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
15:24 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and chicken embryo studies suggest inhibiting FZD8 could help treat prostate cancer. In patient samples, levels of FZD8 were higher in tumors than in adjacent normal prostate tissue. In...
00:12 , May 5, 2018 |  BioCentury  |  Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
18:59 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA accepts NDA for Shire's prucalopride to treat constipation

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review an NDA for prucalopride (SHP555) to treat chronic idiopathic constipation (CIC) in adults. Its PDUFA date is Dec. 21. Shire markets prucalopride, an agonist of serotonin (5-HT4)...
17:30 , Mar 5, 2018 |  BC Extra  |  Company News

FDA reviewing Shire’s constipation treatment

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review its NDA for prucalopride (SHP555) to treat chronic idiopathic constipation (CIC) in adults. Its PDUFA date is Dec. 21. Shire markets prucalopride, an agonist of serotonin (5-HT4)...